Alamar Biosciences priced its IPO at $17 per share, selling 12,937,500 shares and raising about $220 million in gross proceeds. Shares jumped in early trading after beginning to trade on Nasdaq under ticker ALMR. The company plans to use proceeds to advance a clinical version of its Argo HT instrument, with an FDA 510(k) submission planned for next year. Alamar also plans to expand commercial infrastructure and broaden assay content across oncology, cardiology, metabolic disease, and health monitoring, while maintaining a dual-use model for customers building their own tests. For the biotech diagnostics ecosystem, the listing highlights continued appetite for high-sensitivity proteomics and immunoassay platforms paired with regulatory clearance strategies.